398 related articles for article (PubMed ID: 31178422)
1. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
[TBL] [Abstract][Full Text] [Related]
2. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
Lancet Respir Med; 2017 Oct; 5(10):785-794. PubMed ID: 28919201
[TBL] [Abstract][Full Text] [Related]
3. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
Lancet Respir Med; 2024 Apr; 12(4):e21-e30. PubMed ID: 38548406
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
5. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
6. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
[TBL] [Abstract][Full Text] [Related]
7. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
[No Abstract] [Full Text] [Related]
9. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E; Jansa P; Fan F; Hauser JA; Pannaux M; Morganti A; Rofael H; Chin KM
J Am Coll Cardiol; 2024 Jan; 83(4):473-484. PubMed ID: 38267108
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
Chang HJ; Song S; Chang SA; Kim HK; Jung HO; Choi JH; Lee JS; Kim KH; Jeong JO; Lee JH; Kim DK
Clin Ther; 2019 Aug; 41(8):1499-1507. PubMed ID: 31202506
[TBL] [Abstract][Full Text] [Related]
12. Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rosenkranz S; Feldman J; McLaughlin VV; Rischard F; Lange TJ; White RJ; Peacock AJ; Gerhardt F; Ebrahimi R; Brooks G; Satler C; Frantz RP;
Lancet Respir Med; 2022 Jan; 10(1):35-46. PubMed ID: 34425071
[TBL] [Abstract][Full Text] [Related]
13. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Frantz RP; McLaughlin VV; Sahay S; Escribano Subías P; Zolty RL; Benza RL; Channick RN; Chin KM; Hemnes AR; Howard LS; Sitbon O; Vachiéry JL; Zamanian RT; Cravets M; Roscigno RF; Mottola D; Osterhout R; Bruey JM; Elman E; Tompkins CA; Parsley E; Aranda R; Zisman LS; Ghofrani HA;
Lancet Respir Med; 2024 Jul; 12(7):523-534. PubMed ID: 38705167
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R; Delcroix M; Galié N; Jansa P; Mehta S; Pulido T; Rubin L; Sastry BKS; Simonneau G; Sitbon O; Torbicki A; Boyanova N; Chamitava L; Stein C; Channick RN
Adv Ther; 2022 Sep; 39(9):4374-4390. PubMed ID: 35819570
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
[TBL] [Abstract][Full Text] [Related]
17. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
Martynyuk TV; Nakonechnikov SN; Chazova IY
Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
[TBL] [Abstract][Full Text] [Related]
18. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
19. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
Krause A; Zisowsky J; Dingemanse J
Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
[TBL] [Abstract][Full Text] [Related]
20. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
